A Breath of Hope: Liberate Medical's VentFree Aims to Revolutionize ICU Care

CRESTWOOD, KY – March 03, 2026 – Liberate Medical announced it has completed patient enrollment for the pivotal clinical trial of its VentFree® Respiratory Muscle Stimulator, a milestone that moves the novel device one step closer to potentially transforming care for critically ill patients. The 250-patient global study is designed to determine if the technology can shorten the time patients spend on life-sustaining mechanical ventilators, a period fraught with risk and enormous cost.

The completion of the PREVENT trial marks a critical juncture for the company and for the field of critical care, which has long sought better ways to liberate patients from mechanical ventilation. With plans to submit its data to the U.S. Food and Drug Administration (FDA), Liberate Medical is poised to introduce a technology that could address one of the most significant challenges in the modern intensive care unit (ICU).

The High Stakes of Prolonged Ventilation

Each year in the United States, more than 800,000 ICU admissions require mechanical ventilation to breathe. While this intervention is life-saving, every additional day a patient remains on a ventilator increases the risk of severe complications, deteriorates their quality of life, and places a staggering burden on the healthcare system, estimated at $45 billion annually.

Prolonged ventilation is a major driver of these risks. The process of weaning, or liberating, a patient from a ventilator is complex and often unsuccessful on the first attempt. Studies show that weaning failure rates can be as high as 42% after a single spontaneous breathing trial. Such failures can lead to reintubation, a procedure that dramatically increases the risk of ventilator-associated pneumonia (VAP) by as much as seven-fold and is associated with a three-fold rise in mortality risk.

"There has long been a gap in our ability to address respiratory muscle weakness at the bedside while patients are still ventilated," said Kimberly Rengel, Assistant Professor of Anesthesiology Critical Care at Vanderbilt University Medical Center and a principal investigator in the PREVENT study. The problem is that the ventilator, while essential, breathes for the patient, causing respiratory muscles—particularly those used for coughing and forceful exhalation—to weaken and atrophy. This weakness makes it difficult for patients to breathe on their own and clear their airways, a primary cause of weaning failure.

A Novel Approach to Respiratory Muscle Weakness

Liberate Medical's VentFree system aims to solve this problem directly. It is the first non-invasive device that uses neuromuscular electrical stimulation (NMES) synchronized with the patient's own breathing. Small pads placed on the patient's abdomen deliver gentle electrical impulses that contract the expiratory muscles, effectively exercising them during the ventilation period. By strengthening these muscles, the device is designed to improve a patient's ability to cough and breathe independently, facilitating a quicker and more successful transition off the ventilator.

"The clinical rationale for respiratory muscle stimulation during mechanical ventilation is compelling," stated Tim Frenzel, MD, an Intensivist at Radboudumc in the Netherlands, the highest-enrolling site in the trial. The device is already used in routine clinical care at his institution under its European CE mark. "Our experience using VentFree in daily practice reinforces our confidence in this technology."

This approach represents a paradigm shift from passive waiting to active rehabilitation. Instead of merely adjusting ventilator settings, clinicians could use VentFree to proactively condition patients for liberation, potentially preventing the downward spiral of muscle atrophy and prolonged dependency.

Navigating the Path from Breakthrough to Bedside

The journey for any innovative medical device is long and arduous, and VentFree is no exception. Completing enrollment in the PREVENT pivotal trial is a landmark achievement, providing the large-scale, randomized controlled data required for regulatory scrutiny. With this milestone reached, Liberate Medical is preparing to submit a De Novo application to the FDA.

The De Novo pathway is specifically designed for novel, low-to-moderate-risk devices that have no existing market equivalent, or 'predicate.' A successful De Novo classification would not only grant Liberate Medical marketing authorization but also create a new category of device, establishing VentFree as a first-in-class technology.

The device's potential has already been recognized through an FDA Breakthrough Device Designation, which is intended to expedite the development and review of technologies that could provide more effective treatment for life-threatening conditions. Further validation comes from a $6.48 million grant from the U.S. Department of Defense, underscoring the perceived importance of addressing prolonged ventilation.

"Completing enrollment of 250 patients in the PREVENT trial is a landmark milestone for Liberate Medical and for the field of critical care," said Angus McLachlan, CEO of Liberate Medical, in a statement. He noted the company is now focused on building its commercial readiness in anticipation of FDA authorization, signaling a strategic shift from pure research and development to market launch.

Redefining the Standard of Care

While current critical care guidelines emphasize protocolized weaning strategies, such as daily Spontaneous Breathing Trials (SBTs) and early mobilization, they primarily focus on assessing a patient's readiness rather than actively improving it. Advanced ventilator modes can help ease the transition, but they do not address the root cause of respiratory muscle deconditioning in the same way VentFree is designed to.

If the PREVENT trial data proves positive, the VentFree stimulator could be integrated into existing ICU weaning protocols as a new standard. For patients, this could mean fewer days in a sedated state, a lower risk of debilitating infections, and a faster return to their families. For hospitals and healthcare systems, it represents a significant opportunity to reduce ICU length of stay, free up critical bed space, and lower the immense costs associated with complex care.

The final results of the PREVENT trial will be highly anticipated by the critical care community. For the hundreds of thousands of patients who rely on mechanical ventilators each year, the outcome could mark the beginning of a new, safer standard of care.